Summer Certification Sale 70% Discount Offer - Ends in 0d 00h 00m 00s - Coupon code: save70

ASCP-MLT Exam Dumps : MEDICAL LABORATORY TECHNICIAN - MLT(ASCP)

PDF
ASCP-MLT pdf
 Real Exam Questions and Answer
 Last Update: Aug 28, 2026
 Question and Answers: 572
 Compatible with all Devices
 Printable Format
 100% Pass Guaranteed
$25.5  $84.99
ASCP-MLT exam
PDF + Testing Engine
ASCP-MLT PDF + engine
 Both PDF & Practice Software
 Last Update: Aug 28, 2026
 Question and Answers: 572
 Discount Offer
 Download Free Demo
 24/7 Customer Support
$40.5  $134.99
Testing Engine
ASCP-MLT Engine
 Desktop Based Application
 Last Update: Aug 28, 2026
 Question and Answers: 572
 Create Multiple Test Sets
 Questions Regularly Updated
  90 Days Free Updates
  Windows and Mac Compatible
$30  $99.99

Verified By IT Certified Experts

CertsTopics.com Certified Safe Files

Up-To-Date Exam Study Material

99.5% High Success Pass Rate

100% Accurate Answers

Instant Downloads

Exam Questions And Answers PDF

Try Demo Before You Buy

Certification Exams with Helpful Questions And Answers

MEDICAL LABORATORY TECHNICIAN - MLT(ASCP) Questions and Answers

Question 1

Which of the following cardiac biomarkers rises within 30 minutes - 4 hours after chest pain, peaks in 2 - 12 hours, and is usually normal within 24 - 36 hours.

Options:

A.

Cardiac troponins

B.

CK-MB

C.

Myoglobin

Buy Now
Question 2

Secondary granules, also known as specific granules first appear in the myelocyte stage next to the nucleus. In neutrophils this is termed the "dawn of neutrophilia".

What is one of the main characteristics of secondary granules in the neutrophilic granulocyte cytoplasm?

Options:

A.

Appear first at the myelocyte stage

B.

Dissolve in mature granulocytes

C.

Are formed on the mitochondria

D.

Are derived from azurophil (primary) granules

Question 3

Though it may not be required, TDM should still be used to confirm adequate dosing. Genotyping does not make TDM redundant.

A PM will metabolize the drug more slowly and therefore will need lower doses. CYP2D6 metabolizes many different drugs; it is not associated with just one class of drugs. Anytime a drug is taken that competes for the same metabolizing enzyme as another drug, there is potential for the concentrations of both drugs to be increased.

A patient has been characterized as a CYP2D6 poor metabolizer (PM) after genotyping. Which of the following statements is not true?

Options:

A.

The patient will likely need lower doses of CYP2D6-metabolized drugs.

B.

The patient is less likely to require therapeutic drug monitoring (TDM) since the genotype is known.

C.

CYP2D6 metabolizes many drugs, and so attention must be given to the doses of drugs from different classes.